Announced details
Refractory vascular malformations
The product has been designated by the Ministry of Health, Labour and Welfare as an orphan drug. The ministry was not identified as the institution to which the application for marketing approval was submitted.
Orphan drug designation
Ministry of Health, Labour and Welfare
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Information website of the Research Group for Pharmacotherapy of Intractable Hemangiomas and Vascular Malformations
| Item | Details |
|---|---|
| Names of Products / Services Covered | Vascular Malformation Treatment “KP-001” (generic name: ceraverisib phosphate hydrate) |
| Counterparty | Ministry of Health, Labour and Welfare |
| Relationship with the Company | The product has been designated by the Ministry of Health, Labour and Welfare as an orphan drug. The ministry was not identified as the institution to which the application for marketing approval was submitted. |
| Applicable area | Refractory vascular malformations |
| Award/certification name | Orphan drug designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare |
| Source | Information website of the Research Group for Pharmacotherapy of Intractable Hemangiomas and Vascular Malformations |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Treatment options for refractory vascular malformations are extremely limited, resulting in a substantial unmet medical need among patients. The company aims to provide a new treatment option to patients who need it and contribute to their treatment through this product.